STOCK TITAN
  1. Home
  2. Sec-filings
  3. RENB
  4. [8-K] Lunai Bioworks Inc. Reports Material Event

Nasdaq moves to delist Lunai Bioworks (LNAI); hearing set for March 26, 2026

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Lunai Bioworks, Inc. reports that Nasdaq has moved to delist its common stock, but the company has secured a hearing to contest this decision. Lunai requested a review after receiving an initial delisting notice, and Nasdaq’s Hearings Panel has now scheduled a hearing for March 26, 2026.

Because the hearing was granted, the planned delisting is temporarily on hold until the Panel issues a final written decision. The company cautions that there is no assurance the Panel will approve continued listing or that Lunai will meet Nasdaq’s ongoing listing standards going forward.

Positive

  • None.

Negative

  • Nasdaq staff determination to delist: Lunai Bioworks received a formal notice that Nasdaq’s Listing Qualifications Staff has decided to delist its securities, signaling serious non-compliance with continued listing standards and creating meaningful uncertainty over the company’s future trading venue and liquidity.

Insights

Nasdaq delisting process advances, with only a temporary stay in place.

Lunai Bioworks has been notified that Nasdaq staff determined its securities should be delisted, a clear escalation in its listing compliance issues. The company has exercised its right to appeal, and a Nasdaq Hearings Panel has scheduled a review for March 26, 2026.

The granted hearing automatically stays the delisting, so trading may continue on Nasdaq until the Panel issues a written decision. However, Lunai explicitly notes there is no assurance it will secure continued listing or regain full compliance with Nasdaq’s standards.

For investors, the key hinge point is the Panel’s decision after the March 26, 2026 hearing. That outcome will determine whether Lunai remains on Nasdaq or faces a delisting, which could affect trading venue, liquidity, and visibility.

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities
The company received a delisting notice or transferred its listing to a different exchange.
Understanding 8-K Material Events →
false 0001527728 0001527728 2026-02-17 2026-02-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the
Securities ExchangeAct of 1934

 

Date of Report (Date of earliest event reported): February 17, 2026

 

LUNAI BIOWORKS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-38751   45-2259340
(State or other jurisdiction
of incorporation)		   (Commission File Number)   (I.R.S. Employer
Identification No.)

 

3400 Cottage Way, Suite G2, #3256

Sacramento, California 95825

(Address of principal executive offices)

 

+1 (424) 222-9301

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of theAct:

 

Title of Each Class   Trading Symbol   Name of Each Exchange on Which Registered
Common Stock, par value $0.0001 per share   LNAI   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities ExchangeAct of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the ExchangeAct. ☐

 

 

 

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

 

On February 6, 2026, Lunai Bioworks Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Staff had determined to delist the Company’s securities from Nasdaq.

 

As previously disclosed, the Company timely requested a hearing before the Nasdaq Hearings Panel (the “Panel”) to appeal the Staff’s determination.

 

On February 17, 2026, the Company received written notice from Nasdaq that the Panel has granted the Company’s request for a hearing. The hearing has been scheduled for March 26, 2026. As a result of the hearing request, the delisting action referenced in the Staff’s determination letter has been stayed pending a final written decision by the Panel.

 

There can be no assurance that the Panel will grant the Company’s request for continued listing or that the Company will be able to maintain compliance with Nasdaq’s continued listing requirements.

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  LUNAI BIOWORKS, INC.
   
  By: /s/ David Weinstein
  Name: David Weinstein
  Title: Chief Executive Officer
   
Date: February 23, 2026  

 

 

 

 

Source: View Original Filing on SEC EDGAR

FAQ

What Nasdaq action does Lunai Bioworks (LNAI) report in this 8-K?

Nasdaq’s Listing Qualifications Staff has determined to delist Lunai Bioworks’ securities. The company previously received this notice and responded by requesting a hearing, triggering a formal appeals process before a Nasdaq Hearings Panel to contest the delisting determination.

How is Lunai Bioworks (LNAI) responding to Nasdaq’s delisting determination?

Lunai Bioworks requested a hearing before a Nasdaq Hearings Panel to appeal the staff’s delisting decision. Nasdaq has granted this request, allowing the company to present its case regarding continued listing and compliance with Nasdaq’s standards at a scheduled hearing.

When is Lunai Bioworks’ Nasdaq delisting hearing scheduled?

The Nasdaq Hearings Panel scheduled Lunai Bioworks’ hearing for March 26, 2026. At that session, the company can argue for continued listing. The Panel will later issue a written decision determining whether Lunai remains listed or proceeds toward delisting.

Is Lunai Bioworks (LNAI) still listed on Nasdaq pending the hearing?

Yes, the delisting action is currently stayed because Lunai requested and received a hearing. This stay remains in effect until the Hearings Panel issues its final written decision on whether the company can continue to meet Nasdaq’s listing requirements.

Does Lunai Bioworks guarantee continued Nasdaq listing after the hearing?

No, the company explicitly states there can be no assurance the Hearings Panel will grant continued listing. It also cautions there is no guarantee Lunai will be able to maintain compliance with Nasdaq’s ongoing continued listing requirements in the future.

What risk does the Nasdaq delisting process pose for Lunai Bioworks shareholders?

The main risk is potential removal of Lunai’s shares from Nasdaq if the Panel upholds the delisting. That could shift trading to less prominent markets, affecting liquidity, visibility, and possibly transaction costs, depending on the final outcome of the Nasdaq hearing process.

Filing Exhibits & Attachments

3 documents

Other Documents